Table 3 Tumour lesions for the efficacy analysis in patients with mRCC treated with sunitinib

From: Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

 

N

Eligible lesions for analysis

 RECIST

225

 Choi criteria

173

Exclusion according to both RECIST and Choi criteria

26

 Bone metastasis

11

 Primary tumour

10

 Brain metastasis

5

Exclusion according to Choi criteria only

52

 10 mm ⩽ tumour lesion at baseline <15 mm

38

 Air-containing cavity at evaluation

8

 Beam-hardening artefact obscuring helical CT density (e.g. metal-containing parts)

6

  1. Abbreviations: RECIST=Response Evaluation Criteria in Solid Tumours; CT=computed tomography.
Back to article page